Direkt zum Inhalt
Merck

Fortfahren mit

B302-05

Bovine Pulmonary Artery Endothelial Cells: BPAEC (Cryovial)

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
Ihnen/SKUVerfügbarkeitPreis

Über diesen Artikel

NACRES:
NA.81
UNSPSC Code:
41106514
Biological source:
bovine pulmonary artery (USDA-inspected cattle)
Growth mode:
Adherent
Morphology:
Endothelial
Relevant disease(s):
diabetes; cardiovascular diseases
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


biological source

bovine pulmonary artery (USDA-inspected cattle)

packaging

pkg of 500,000 cells

manufacturer/tradename

Cell Applications, Inc

growth mode

Adherent

karyotype

2n = 60

morphology

Endothelial

technique(s)

cell culture | mammalian: suitable

relevant disease(s)

diabetes; cardiovascular diseases

storage temp.

−196°C

General description

Lot specific orders are not able to be placed through the web. Contact your local sales rep for more details.

Bovine large artery endothelial cells (BPAEC) provide an excellent model system to study many aspects of cardiovascular function and disease, for example to investigate critical signaling pathways and mechanisms relevant to proper endothelial function, such as angiogenesis, permeability, NO production, etc., and search for beneficial modulators for therapeutic use, study diabetes-associated complications related to cardiovascular function, investigate mechanisms of endothelial dysfunction related to environmental pollution, smoking, oxidative stress and inflammation and search for potential treatments, and develop layered co-cultures of liver and endothelial cells that demonstrate superior liver-specific features.

BPAEC have been utilized in multiple research publications, for example to:
  • Determine that induction of cellular antioxidant glutathione during moderate oxidative stress involves ARE-binding factors in a MAP kinase independent mechanism (Day, 2003)
  • Show that HGF transiently increases transcription of angiotensin-converting enzyme gene via activation of Egr-1, whereas PMA regulation involves Egr-1 and additional factors (Day, 2004)
  • Elucidate the therapeutic effects of Angiotensin I-converting enzyme (ACE) inhibitors, and the results revealed that they provide an additional benefit to patients by activating bradykinin B1 receptor leading to prolonged nitric oxide (NO) production in endothelial cells (Ignjatovic, 2004)
  • Demonstrate that thiol-reactive compounds in cigarette smoke activate NADPH oxidase and increase superoxide anion production, reducing NO levels and resulting in endothelial dysfunction (Jaimes, 2004)
  • Reveal that mercury, a risk factor for cardiovascular diseases, induces PLA2 activation in endothelial cells, followed by PLD activation, and the process is mediated by thiol-redox alteration, ROS and Ca2+/calmodulin (Hagele, 2006, 2007; Mazerik, 2007; Peltz, 2009; Sherwani, 2013)
  • Demonstrate that adiponectin protects against the hyperoxia-induced endothelial barrier dysfunction and lung damage by relieving oxidative stress and normalizing thiol-redox status (Sliman, 2013)
  • Show that TGF-β1–induced endothelial permeability involves focal adhesion and cytoskeletal rearrangement through both FAK/Src-dependent and -independent pathways (Lee, 2007)
  • Demonstrate that exposure to lipopolysaccharides inhibits AMPK (which is required for normal endothelial barrier function) and causes endothelial hyperpermeability and lung injury (Xing, 2013)
  • Demonstrate the effectiveness of myosin light chain kinase inhibitors in decreasing endothelial hyperpermeability (Marchenko, 2010)
  • Show that angiotensin II-induced apoptosis relies on activation of AMPK for ATP production, as well as for activation of SHP-2 in a signaling cascade leading to Bcl-x(L) mRNA destabilization (Day, 2011)
  • Evaluate therapeutic potential of aminoguanidine in protecting endothelia from hyperglycemic complications in diabetes by blocking the reactivity of the sugar-derived dicarbonyls and preventing the formation of advanced glycation end products (Sliman, 2010)
  • Demonstrate the roles of Egr-1, ATF-2 and Ets-1 in the regulation of angiotensin converting enzyme promoter by phorbol ester (Mungunsukh, 2008)
  • Develop a therapeutic peptide based on a fragment of Listeria monocytogenes internalin B that prevented angiotensin II-induced apoptosis and stimulated proliferation and cell motility by activating ERK1/2, STAT3, and phosphatidylinositol 3-kinase/Akt pathways (Mungunsukh, 2010)
  • Develop layered co-cultures of liver and endothelial cells that demonstrate superior liver-specific features (Ohno, 2008, 2009a, b)

Application

cardiovascular function, screening of drug candidates, angiogenesis, vasodilator function, transport of deoxygenated bloood from heart to lungs

Biochem/physiol Actions

Artery

Preparation Note

  • 2nd passage, >500,000 cells in Bovine Endothelial Cell Growth Medium containing 10% FBS & 10% DMSO
  • Can be cultured at least 16 doublings
Please refer to the BPAEC Culture Protocol.

Other Notes

Bovine Endothelial Cell Growth Medium containing 10% FBS & 10% DMSO


Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Questions

Reviews

No rating value

Active Filters